Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.

MLA

DeFilipp, Zachariah, et al. “Clinical Response to Belumosudil in Bronchiolitis Obliterans Syndrome: A Combined Analysis from 2 Prospective Trials.” Blood Advances, vol. 6, no. 24, Dec. 2022, pp. 6263–70. EBSCOhost, https://doi.org/10.1182/bloodadvances.2022008095.

APA

DeFilipp, Z., Kim, H. T., Yang, Z., Noonan, J., Blazar, B. R., Lee, S. J., Pavletic, S. Z., & Cutler, C. (2022). Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials. Blood Advances, 6(24), 6263–6270. https://doi.org/10.1182/bloodadvances.2022008095

Chicago

DeFilipp, Zachariah, Haesook T Kim, Zhongming Yang, John Noonan, Bruce R Blazar, Stephanie J Lee, Steven Z Pavletic, and Corey Cutler. 2022. “Clinical Response to Belumosudil in Bronchiolitis Obliterans Syndrome: A Combined Analysis from 2 Prospective Trials.” Blood Advances 6 (24): 6263–70. doi:10.1182/bloodadvances.2022008095.